IgA nephropathy (IgAN) is characterized by the presence of IgA deposits in the glomerular mesangium, representing a prevalent form of primary glomerulonephritis worldwide. This condition is associated with a significant risk of progression to end-stage renal disease (ESRD). Hypertension, proteinuria, and reduced glomerular filtration rate (GFR) are established risk factors. Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently the first-line treatments, they do not adequately mitigate the risk of disease progression. Budesonide is a potent corticosteroid that has been utilized for many years in the treatment of inflammatory diseases. Recently, a novel formulation, targeted-release budesonide (TRF-budesonide), was developed to facilitate drug release specifically in the distal ileum to treat IgAN. This review synthesizes the existing evidence on the impact of TRF-budesonide in IgAN, covering its pathogenesis, efficacy, and safety. It also explores comparisons between TRF-budesonide and other therapeutic options, highlighting the advantages of TRF-budesonide in reducing proteinuria and preserving renal function. While TRF-budesonide has demonstrated promising efficacy and safety in short- and medium-term studies, showcasing its potential as a valuable treatment option for IgAN, further high-quality randomized controlled trials are needed to comprehensively evaluate its long-term efficacy and safety. Such research will pave the way for more personalized and precise treatment options for patients with IgAN.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889547 | PMC |
| http://dx.doi.org/10.1016/j.heliyon.2025.e42729 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma.
Blood
March 2025
Sungkyunkwan university school of medicine, Samsung Medical Center, Seoul, Korea, Republic of.
This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-PD1 antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) intravenously every four weeks for six cycles.
View Article and Find Full Text PDFAI-Driven Discovery of Highly Specific and Efficacious hCES2A Inhibitors for Ameliorating Irinotecan-Triggered Gut Toxicity.
J Med Chem
March 2025
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine; Shanghai Frontiers Science Center of TCM Chemical Biology; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
The anticancer agent irinotecan often induces severe delayed-onset diarrhea, inhibiting human carboxylesterase 2A (hCES2A) can significantly alleviate irinotecan-triggered gut toxicity (ITGT). This work presents an efficient workflow for design and developing novel efficacious hCES2A inhibitors. A well-training machine learning model identified as a lead compound, while compound was developed as a novel time-dependent hCES2A inhibitor (IC = 0.
View Article and Find Full Text PDFTargeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab's Efficacy and Utilization.
Skin Therapy Lett
March 2025
Center for Clinical Studies, Webster, TX, USA.
Psoriatic arthritis (PsA) is a chronic, inflammatory disease with heterogeneous clinical features. The pathogenesis of PsA involves a complex interplay of genetic, immunologic, and environmental factors, leading to the activation of the immune system and subsequent inflammation. Over the past decade, the understanding of the immune mechanisms underlying PsA has advanced significantly, particularly regarding the role of the interleukin-23/T helper 17 pathway in the disease process.
View Article and Find Full Text PDFIn vitro maturation of oocytes (IVM): historical landmarks, current status and future perspectives.
Syst Biol Reprod Med
December 2025
Laboratory of Histology and Embryology, Aristotle University Medical School, Thessaloniki, Greece.
One of the major advancements in fertilization (IVF) has been the development of culture media that enhance gamete maturation and sustain embryo development up to the blastocyst stage. The deep understanding of the mechanisms involved in gametogenesis and the complex sequence of events surrounding nuclear and cytoplasmic maturation has also enabled the development of efficient maturation (IVM) protocols. This review outlines the major landmarks in the history of maturation of oocytes, the advantages and importance of its clinical application in human, especially in patients with Polycystic Ovary Syndrome (PCOS), Resistant Ovary Syndrome, high antral follicle count or oncology patients, as well as the safety and efficacy of the technique.
View Article and Find Full Text PDFRoflumilast for the Treatment of Seborrheic Dermatitis: A Review.
Skin Therapy Lett
March 2025
University of Central Florida/HCA Healthcare Consortium, Tallahassee, FL, USA.
Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!